AVROBIO, Inc. vision is to bring personalized gene therapy to the world. They aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Their clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and they also are advancing a preclinical program…More in Pompe disease. AVROBIO is powered by the plato® gene therapy platform, their foundation designed to scale gene therapy worldwide. They are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.